Peptides - Compound guides
Tirzepatide
Tirzepatide is a dual GLP-1 and GIP receptor agonist and a prescription-only medicine in the UK, available only after clinical assessment by a prescriber. This page explains the pharmacology and the trial record; it is not a recommendation to obtain or use it.
Tirzepatide is a synthetic peptide that activates two incretin receptors: the GLP-1 receptor and the GIP receptor. Its sequence is based on native GIP and modified so that it binds both receptors and resists the enzymes that would normally clear an incretin hormone from the blood within minutes, giving it a duration of action measured in days rather than minutes. It was developed first as a treatment for type 2 diabetes and subsequently studied and licensed for weight management in people with obesity or overweight with weight-related health conditions. In the UK it is marketed under brand names including Mounjaro, named here only so readers can recognise what they are reading about.
Tirzepatide is a licensed prescription-only medicine in the UK. That status is the central practical fact about it, and it is covered in full below.
How it works
GLP-1 and GIP are gut hormones, released from the intestinal wall when a meal is eaten. They are called incretins because they explain why glucose taken by mouth triggers a larger insulin response than the same amount of glucose given intravenously - the gut is signalling ahead to the pancreas. GLP-1 stimulates insulin release in a glucose-dependent way, meaning it prompts insulin only when blood glucose is elevated, which is why the incretin mechanism does not drive glucose down indefinitely on its own. GLP-1 also suppresses the release of glucagon after meals, slows gastric emptying so that food leaves the stomach more gradually, and acts directly on appetite-regulating regions of the brain, notably in the hypothalamus and the brainstem, to increase satiety and reduce hunger.
GIP is the other major incretin. It also amplifies glucose-dependent insulin secretion, and it has effects on adipose tissue and, through receptors in the brain, on appetite and on nausea signalling. Tirzepatide is an agonist at both receptors - it binds them and switches them on. The practical consequences observed in trials are better post-meal glucose control, slower gastric emptying, reduced appetite and reduced food intake. The pharmacology here is well characterised and is not in dispute; what varies between individuals is the size of the response and the tolerability of the gastrointestinal effects.
What the research actually shows
Tirzepatide has been tested in two large phase 3 programmes. The SURPASS programme studied it in adults with type 2 diabetes, with change in HbA1c as the primary endpoint across trials that compared tirzepatide against placebo and against active comparators including insulin and a GLP-1 receptor agonist. The SURPASS trials measured change in HbA1c against placebo and against active comparators, with weight reduction recorded as a secondary finding. Those results were assessed by regulators as part of the licensing process; what they mean for any individual is a matter for a prescriber.
The SURMOUNT programme studied tirzepatide for weight management. In the phase 3 SURMOUNT-1 trial, adults with obesity, or with overweight plus at least one weight-related condition and without diabetes, were randomised to placebo or to tirzepatide and treated for 72 weeks, with percentage change in body weight as the primary endpoint. Participants receiving tirzepatide lost more body weight on average than those receiving placebo over the trial period. SURMOUNT-2 examined weight reduction in adults with obesity and type 2 diabetes and reported a smaller average effect than in the non-diabetic population, a pattern seen with incretin drugs generally. Further trials in the programme have examined outcomes including obstructive sleep apnoea and the effect of continuing versus stopping treatment.
What these trials measure matters. Most measured weight and glucose control over months to a small number of years in supervised populations with regular clinical contact. They are strong evidence about those endpoints in those populations. They are not evidence about what happens over decades, and trial populations are selected in ways that real-world populations are not.
Risks, side effects and what is still unknown
- Gastrointestinal adverse effects are the most common in trials - nausea, vomiting, diarrhoea, constipation and abdominal discomfort - and were the leading cause of participants discontinuing treatment.
- Pancreatitis, gallbladder disease including gallstones, and thyroid C-cell tumours observed in rodent studies are the labelled safety concerns for the incretin class, and product information carries warnings accordingly. Whether the rodent thyroid finding translates to humans remains unresolved.
- Risk of hypoglycaemia rises when an incretin drug is combined with other glucose-lowering medicines such as insulin or sulfonylureas, which is one of the reasons prescribing requires review of a person's full medication list.
- A significant proportion of the weight lost is lean mass rather than fat. This is a recognised concern with rapid weight reduction and is one reason clinical supervision, nutrition and resistance exercise are discussed alongside treatment.
- Weight regain on discontinuation is well documented. Trials that withdrew treatment saw participants regain a substantial share of the weight lost, indicating that the effect depends on continued treatment rather than producing a lasting reset.
- Effects on the developing fetus are not established and pregnancy is a specific consideration a prescriber must assess.
- Long-term outcome data are still accumulating. Multi-decade safety and the effects in people who would have been excluded from the trials are not yet known.
Legal status in the UK
Tirzepatide is a licensed prescription-only medicine in the UK. It is legally available only on a prescription written after a clinical assessment by an appropriately qualified prescriber, and dispensed by a registered pharmacy. It is not a supplement, it is not a consumer product, and there is no lawful route by which it reaches a member of the public without that assessment and that pharmacy. Supplying a prescription-only medicine without a prescription is a criminal offence.
The MHRA has repeatedly warned about counterfeit and falsified GLP-1 pens sold outside the regulated supply chain, through social media, messaging apps and beauty or cosmetic outlets. Some seized falsified pens were found to contain insulin rather than the labelled drug, and people who used them were hospitalised with severe hypoglycaemia. Falsified products have also been found unsterile, incorrectly dosed or containing nothing active at all. A pen bought outside a registered pharmacy carries none of the identity, purity and manufacturing guarantees that licensing exists to provide. Tirzepatide is also prohibited in sport under World Anti-Doping Agency rules for athletes subject to testing.
This page is educational information only and is not medical advice. Tirzepatide is a prescription-only medicine and nothing here should be read as a recommendation to take, obtain or consider it. Decisions about weight, diabetes or any treatment belong with a qualified healthcare professional who can assess your individual circumstances.
Metabolic and incretin compounds
Start with the overview: How research peptides are grouped into families
Further reading
Sources for this classroom
Educational content only. Not medical advice, diagnosis or treatment. Always consult a qualified healthcare professional before changing your health regimen.
